eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | squamous cell carcinoma of head and neck |
| Comorbidity | C0334246|metastatic squamous cell carcinoma |
| Sentences | 8 |
| PubMedID- 25909285 | In patients with recurrent or metastatic squamous cell carcinoma of the head and neck, stable disease with minor tumor shrinkage was found in half of patients received foretinib treatment and a combinational therapy with targeted agents or cytotixic chemotherapy was suggested [30]. |
| PubMedID- 24567516 | Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (r/m-scchn) have a poor prognosis. |
| PubMedID- 22485156 | Then, we tested whether preincubation with cxcl12 before adding [18f]msx-122f blocked binding to cxcr4 in the cxcr4-positive metastatic squamous cell carcinoma of head and neck (scchn) cells that we established from a poorly metastatic parental cell line by four rounds of in vivo selection using a lymph node metastatic xenograft mouse model. |
| PubMedID- 21269250 | Cilengitide added to cisplatin, 5-fluorouracil (5-fu), and cetuximab is also being evaluated in an open-label, randomized, controlled phase i/ii study (advantage) in subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck (scchn) [140, 143]. |
| PubMedID- 20335368 | For patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (scchn), platinum has been an integral part of palliative care for about the past 30 years. |
| PubMedID- 20459770 | [17] described that cetuximab was effective in combination with platinum-based regimens for recurrent or metastatic squamous cell carcinoma of the head and neck. |
| PubMedID- 23150825 | The trial enrolled 657 patients with recurrent or metastatic squamous cell carcinoma of the head and neck who were randomized to platinum-based (cisplatin or carboplatin) chemotherapy + 5-fu or panitumumab in combination with platinum/5-fu therapy and measured overall survival as the primary endpoint. |
| PubMedID- 22408457 | The us nih repository for clinical trials reports some trials involving epigenetic-based drugs in head and neck cancer treatment: azacitidine and cisplatin have been tested in combined chemotherapy in advanced, recurrent and metastatic squamous cell carcinoma of head and neck but no data are available to date about the outcome of the study [154]. |
Page: 1